MnB rLP2086 (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/mnb-rlp2086-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

MnB rLP2086 is Pfizer’s recombinant protein vaccine that protects against MenB disease. Despite Pfizer’s position as a major player in the vaccine industry, MnB rLP2086 is currently the only meningococcal vaccine in the pharmaceutical giant’s portfolio. Originally developed by Wyeth, Pfizer acquired MnB rLP2086 with its purchase of the company in 2009. MnB rLP2086 is a bivalent vaccine composed of two variants of the N. meningitidis OMP LP2086, A05, and B01. LP086 is a lipoprotein (LP) linked to the outer membrane of the bacteria and promotes in vivo survival by binding Factor H and facilitating complement evasion.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on MnB rLP2086 including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for MnB rLP2086 for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of MnB rLP2086 performance

Obtain sales forecast for MnB rLP2086 from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 6

2 Introduction 7

2.1 Catalyst 7

2.2 Related Reports 8

3 Disease Overview 10

3.1 Etiology and Pathophysiology 10

3.1.1 Etiology 10

3.1.2 Pathophysiology 12

3.2 Symptoms 13

3.3 Prognosis 14

4 Disease Management 15

4.1 Meningococcal Immunization Policy 16

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171856

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074